RESEARCH ARTICLE Angiopoietin-2 as a Prognostic Biomarker of Major Adverse Cardiovascular Events and All- Cause Mortality in Chronic Kidney Disease

Background Chronic kidney disease (CKD) patients have higher prevalence of major adverse cardiovas-cular events (MACE) and all-cause mortality. Endothelial damage and dysfunction have been regarded as early portents of MACE in CKD patients. Angiopoietin-2 (Ang-2) impairs endothelial function and promotes aberrant neovascularization. The aim of the study was to assess the relationship between circulating Ang-2 and MACE or all-cause mortality in a CKD cohort. Methods A total of 621 pre-dialysis stage 3–5 CKD patients were enrolled from January 2006 to December 2011 and were followed up till October 2014. Plasma Ang-2 was measured in duplicate using commercial enzyme-linked immunosorbent assays (ELISA). Clinical out-comes included MACE or all-cause mortality Results Of all patients, 122 (19.8%) reached MACE or all-cause mortality. Seventy-two had MACE